YLYuhui Li

Yuhui Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yuhui Li has a total of 136 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Low-Dose Interleukin-2 for Cancer-Associated Myositis: a Prospective Multicentre Proof-Of-Concept Cohort Study

    by Liang Zhao, Xiaojuan Gao, Yuhui Li, See Pdf

    Background: Cancer-associated myositis (CAM) is associated with substantial morbidity and mortality, and treatment is complicated by concern that non-selective immunosuppression could impair antitumour immunity. Low-dose interleukin-2 (Ld-IL2) selectively expands regulatory T cells. We assessed the clinical activity, immunological effects, and short-term oncological safety of Ld-IL2 in patients with CAM.Methods: In this prospective, multicentre, proof-of-concept cohort study, adults with CAM and active myositis despite standard treatment, or for whom further immunosuppressive escalation was considered unsuitable, received subcutaneous Ld-IL2 (1 million IU every other day) in addition to stable background treatment for 24 weeks at four tertiary centres in China. The primary outcome was clinical improvement at week 24 according to the 2016 American College of Rheumatology–European Alliance of Associations for Rheumatology Total Improvement Score (TIS). Clinical, immunological, oncological, and safety outcomes were assessed in the treated cohort. An exploratory comparison of overall survival was made with a non-randomised, contemporaneous historical cohort receiving conventional treatment.Findings: Between Sep 1, 2021 and Jan 30, 2026, 101 patients were screened across four participating centres and 48 were included: 17 in the prospective Ld-IL2 cohort and 31 in the historical-control cohort. All 17 treated patients completed 24 weeks of follow-up. At week 24, 15 (88%) of 17 patients had at least minimal improvement (TIS ≥20), including five (29%) with moderate improvement and four (24%) with major improvement. Median Manual Muscle Testing-8 (MMT-8) score increased from 134·0 (IQR 128·0–142·0) to 144·0 (138·0–144·0; p<0·001), mean Cutaneous Dermatomyositis Disease Area and Severity Index activity score decreased from 7·47 (SD 5·72) to 4·18 (3·41; p<0·001), and median daily prednisone dose decreased from 10·0 mg (IQR 5·0–30·0) to 7·5 mg (5·0–10·0; p=0·003). Among 12 patients with paired immunophenotyping, the mean proportion of FoxP3+ regulatory T cells increased from 8·22% (SD 2·57) to 12·24% (4·72; p=0·022). Among 15 patients evaluable by Response Evaluation Criteria in Solid Tumours version 1.1, no progressive disease was observed by week 24. No serious adverse events, severe infections, or treatment discontinuations were reported. In the exploratory historical comparison, no deaths occurred in the treated cohort and five occurred in the historical-control cohort; this survival analysis should be considered hypothesis-generating.Interpretation: Add-on Ld-IL2 was associated with improvement across several myositis domains, glucocorticoid sparing, and expansion of circulating regulatory T cells over 24 weeks, without an observed short-term signal of tumour progression. The small uncontrolled cohort, heterogeneous cancers and anticancer treatments, and non-randomised historical comparison preclude conclusions about comparative efficacy, long-term oncological safety, or survival. Controlled studies with prespecified oncological outcomes and longer follow-up are warranted.

  • Open Access

    Elevated Peripheral CD161 + Treg Cells and Their Clinical Significance in Behçet Syndrome

    by Jiachen Li, Weiyi Xia, Feng Sun, Yingni Li, Yuke Hou, Huanhuan Ren, Xiaolin Sun, Yuhui Li, Zhanguo Li, Tian Liu

    Objective: Behçet syndrome (BS) is a systemic autoimmune vasculitis characterized by immune dysregulation involving multiple immune cell subsets. CD161 + Treg cells exhibit proinflammatory properties and impair immune regulation during inflammation. This study aimed to investigate the alterations in CD161 + Treg cells in BS and their clinical relevance, particularly in disease pathogenesis and neurologic involvement. Methods: This prospective multicenter study included 182 patients diagnosed with BS at the three hospitals between 2018 and 2024, 166 patients with systemic lupus erythematosus (SLE) and 149 patients with rheumatoid arthritis (RA) and 114 patients with healthy controls (HCs). Demographic and clinical data were recorded. CD4 + CD25 high CD127 low CD161 + T cells (CD161 + Treg cells) in peripheral blood were analyzed via flow cytometry. Statistical analysis included the Wilcoxon rank‐sum test, Fisher's exact test, and logistic regression, with P < 0.05 considered significant. Results: Patients with BS had a significantly higher proportion among total Treg cells and CD4 + T cells, as well as higher absolute number of CD161 + Treg cells compared to HCs. CD161 + Treg cell levels negatively correlated with Foxp3 + Treg cells and positively correlated with Teff cells. Patients with BS had higher absolute number of CD161 + Treg cells than that in patients with SLE and in patients with RA. Moreover, patients with BS with higher erythrocyte sedimentation rate or C‐reactive protein or with neurologic involvement exhibited higher CD161 + Treg cells, which were identified as a risk factor for neurologic involvement. Among 41 patients with BS observed after treatment, CD161 + Treg cells significantly decreased, correlating with reduced disease activity. Conclusion: Patients with BS exhibit an increased CD161 + Treg cells in peripheral blood, which may contribute to immune dysregulation and neurologic involvement. The reduction of CD161 + Treg cells following treatment suggests their potential role as a biomarker for disease activity in BS.

  • Open Access

    Precision and cellular therapies for adult idiopathic inflammatory myopathies: Recent advances

    by Xiaoyan Xing, Wanxing Mo, Liang Zhao, Shumin Zhang, Naidi Wang, Kai Zhang, Jing Zhao, Dan Lu, Yuhui Li, Jing He

    Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of autoimmune diseases with variable extramuscular involvement and diverse treatment responses. Although glucocorticoids and conventional immunosuppressants remain the cornerstone of therapy, refractory disease and treatment intolerance are still common. Emerging biologic, pathway-based, and cellular therapies are expanding treatment options, particularly for selected patients with refractory disease, although the strength of evidence and current clinical applicability vary among approaches. Meanwhile, advances in single-cell and spatial omics are improving understanding of disease heterogeneity and facilitating more precise treatment stratification. This review summarizes current and emerging therapies for adult IIMs, with an emphasis on their clinical relevance, phenotype-specific application, and the evolving role of biomarker-informed precision medicine in refractory disease.

  • [Rheumatic disease spectrum and immunological profile of anti-PM/Scl antibodies in idiopathic inflammatory myopathies].

    by Yirui Lian, Jingxuan Liu, Liang Zhao, Jing Zhao, Sitian Zang, Yuhui Li

    To systematically investigate the rheumatic disease spectrum associated with anti-PM/Scl antibodies and to clarify their clinical significance in idiopathic inflammatory myopathies (IIM). Patients who were tested positive for anti-PM/Scl antibodies by immunoblotting at Peking University People' s Hospital from January 2016 to December 2024 were enrolled. Clinical and immunolo gical data were systematically collected and compared across the subgroups defined by anti-PM/Scl75, anti-PM/Scl100, or dual antibody positivity. A total of 422 anti-PM/Scl-positive patients were enrolled. Among them, 83.2% (351/422) were diagnosed with connective tissue disease (CTD), 7.8% (33/422) were not diagnosed with CTD, and 9.0% (38/422) had an undetermined clinical diagnosis. Among 422 patients, most commonly represented by IIM (19.7%), systemic sclerosis (SSc, 14.2%), overlap syndrome (11.8%), undifferentiated CTD (UCTD, 10.4%), rheumatoid arthritis (6.9%), Sjögren syndrome (6.4%), and systemic lupus erythematosus (6.2%), the remaining diseases accounting for 24.4%. Within the IIM subgroup, dermatomyositis predominated (74.7%), followed next by anti-synthetase syndrome (21.7%) and immune-mediated necrotizing myopathy (3.6%). Anti-PM/Scl75 antibodies were detected in 52.1% (220/422) of the total patients, anti-PM/Scl100 in 43.6% (184/422), and both in 4.3% (18/422). In the subsequent detailed analysis of the anti-PM/ Scl-positive subgroup, double-positive patients showed a significantly higher prevalence of SSc (38.9% vs. 14.1% vs. 12.0%, P=0.015) and interstitial lung disease (ILD, 70.6% vs. 28.8% vs. 35.4%, P=0.002) than those individuals with single antibody positivity alone. Raynaud phenomenon was observed more frequently in both the double-positive and anti-PM/Scl75-positive groups than in the anti-PM/Scl100-positive group (29.4% vs. 21.3% vs. 10.9%, P=0.007). The measured proportion of peri-pheral CD8+ T cells was also higher in double-positive patients (35.9%±14.1% vs. 30.4%±11.2% vs. 26.5%±9.7%, P= 0.008), whereas absolute regulatory T-cell levels were lower in the anti-PM/Scl75-positive group compared directly with the anti-PM/Scl100-positive group [7.6% (5.4%, 10.9%) vs. 9.0% (7.9%, 12.0%) vs. 8.8% (5.2%, 9.7%), P=0.017]. Additionally, co-positivity for anti-PM/Scl and other myositis- specific or myositis-associated antibodies was strongly associated with an increased frequency of ILD (P < 0.05). Anti-PM/Scl antibodies define a broad disease spectrum encompassing IIM, SSc, overlap syndromes, and UCTD. Dual positivity for anti-PM/Scl75 and anti-PM/Scl100 identifies patients prone to systemic sclerosis and pulmonary involvement, suggesting additive pathogenic effects of the two antibody specificities.

  • Anti-melanoma differentiation-associated gene-5 antibody-positive dermatomyositis with liver dysfunction: a warning sign of higher death risk

    by Wanxing Mo, Xiaoyan Xing, Suhong Zhai, Meixia Peng, Luqi Wang, Jian Zhang, Chenglong Shi, Jingtian Li, Dan Lu, Yuhui Li, et al.

    This study aimed to investigate and analyze the clinical and immunological features of patients with anti-melanoma differentiation-associated gene-5 antibody-positive dermatomyositis (MDA5 + DM) complicated with clinical liver dysfunction. A cohort of 85 patients diagnosed with MDA5 + DM admitted into Peking University People’s Hospital from 2006 to 2023 were retrospectively enrolled in this study. Clinical characteristics and survival status were collected and analyzed. Clinical liver dysfunction occurred in 28% (24/85) of MDA5 + DM patients. Patients with clinical liver dysfunction were more likely to have muscle impairment (83.3% vs. 52.5%, P = 0.009) and rapidly progressive ILD (72.7% vs. 47.4%, P = 0.027). Lactate dehydrogenase (LDH) (378.5 (296.0,453.8) U/L vs. 280.0 (218.0,355.0) U/L, P = 0.002) and ferritin (FER) (883.0 (279.8,2100.5) ng/mL vs. 293.5.0 (84.0,862.7) ng/mL, P = 0.040) were significantly elevated and total numbers of lymphocytes (827.2 ± 517.2 /μL vs. 1301.8 ± 720.9 /μL, P = 0.042), and CD4 + T cells (403.8 ± 315.9 /μL vs. 548.6 ± 257.7 /μL, P = 0.045) were significantly decreased in patients with clinical liver function. Muscle weakness (OR 5.184, 95% CI 1.305, 20.595, P = 0.019) was identified as an independent risk factor for clinical liver dysfunction. Clinical liver dysfunction was identified as an independent risk factor for poor prognosis in patients with MDA5 + DM (HR = 4.030, 95% Cl 1.233, 13.176, P = 0.021), with an 18-month survival rate of 69%. Liver dysfunction is one of the extramuscular manifestations in patients with MDA5 + DM and might be associated with a poor prognosis. Key Points There were 28% of patients with MDA5 + DM in our study who experienced clinical liver dysfunction, showing different features compared to patients without clinical liver dysfunction: • Clinical liver dysfunction was defined as an AST or ALT level more than double the ULN and the AST or ALT level divided by its ULN was greater than the CK level divided by its ULN. In addition to these two aminotransferases, GGT, ALP, and HBDH, LDH and ferritin were also found to be elevated in patients with clinical liver dysfunction.The proportion and total number of lymphocytes, and the number of CD4 + T cells were all lower in these patients. • Patients with clinical liver dysfunction were more likely to suffer from RP-ILD and muscle involvement, including myalgia and muscle weakness, and multivariate logistic regression analysis demonstrated that muscle weakness was identified as an independent factor for clinical liver dysfunction. • Patients with clinical liver dysfunction seemed to have a poor prognosis. The mortality rate was greater, and the overall survival was shorter. Moreover, clinical liver dysfunction was identified as an independent risk factor for the poor prognosis.


  • 特发性炎性肌病完全临床应答相关因素的单中心真实世界研究

    by Zhanhong Lai, Jiachen Li, Zelin Yun, Yonggang Zhang, Hao Zhang, Xiaoyan Xing, Miao Shao, Yuebo Jin, Naidi Wang, Yimin Li, et al.

    探究影响特发性炎性肌病(idiopathic inflammatory myopathies,IIMs)患者对常规治疗完全临床应答的相关因素。 纳入2000年1月至2023年6月于北京大学人民医院就诊的IIMs患者,通过分析患者的临床特征、实验室检查、免疫学指标和治疗用药,明确影响患者对常规治疗完全临床应答的相关因素。 共纳入635例IIMs患者,其中518例患者完成随访,平均随访时间36.8个月,总体完全临床应答率为50.0%(259/518)。各临床亚型中,皮肌炎(dermatomyositis,DM)、抗合成酶综合征(anti-synthetase syndrome,ASS)和免疫介导坏死性肌病(immune-mediated necrotizing myopathy,IMNM)的完全临床应答率分别为53.5%、48.9%和39.0%。未完全临床应答组与完全临床应答组相比,在临床特征方面,发热(P=0.002)和快速进展型间质性肺病(rapid progressive interstitial lung disease,RP-ILD)(P=0.014)的发生率较高;在实验室检查方面,谷草转氨酶、乳酸脱氢酶、D-二聚体、红细胞沉降率、C反应蛋白和血清铁蛋白水平较高;在治疗用药方面,激素和静脉注射免疫球蛋白(intravenous immunoglobin,IVIG)的使用比例均较高。IMNM(P=0.007)、间质性肺病(P=0.001)、谷草转氨酶高(P=0.012)、血清铁蛋白高(P=0.016)和外周血CD4+T细胞计数低(P=0.004)是IIMs未完全临床应答的危险因素。 IIMs患者的总体完全临床应答率低,IMNM亚型最低; 起病时存在间质性肺病、谷草转氨酶高、血清铁蛋白高或外周血CD4+T细胞计数低的患者应给予积极治疗。

  • Clinical and immunological characteristics and prognosis of patients with autoantibody negative dermatomyositis: a case control study

    by Xiaoyan Xing, Yuzhou Gan, Wanxing Mo, Jian Zhang, Naidi Wang, Kai Zhang, Ke Ma, Lihua Zhang, Lin Ma, Dan Lu, et al.

    Objectives Myositis-specific antibodies (MSAs) and myositis-associated antibodies (MAAs) are associated with distinctive dermatomyositis (DM) clinical phenotypes. The aim of this study is to explicate the clinical and immunological features of MSAs-negative DM patients. Methods A total of 515 individuals diagnosed with DM was screened from 2013 to 2022 and 220 DM patients were enrolled in this retrospective cohort. Clinical and laboratory data of these patients were analyzed. Results MSAs-negative DM patients were categorized into two groups: MAAs-negative (MSAs (−)/MAAs (−)) group and MAAs-positive (MSAs (−)/MAAs (+)) group. The percentage of Raynaud’s phenomenon (P=0.026) was higher in the MSAs (−)/MAAs (+) DM patients than the MSAs-positive DM patients and MSAs (−)/MAAs (−) DM patients. The proportion of rapidly progressive interstitial lung disease (RP-ILD) in the MSAs-negative DM patients was lower than that in the MSAs-positive group. The MSAs (−)/MAAs (+) group had a higher proportion of organizing pneumonia and usual interstitial pneumonia (P=0.011), and elevated eosinophils in their bronchoalveolar lavage fluid (P=0.008). Counts of lymphocytes (P=0.001) and CD16+CD56+ natural killer (NK) cells (P=0.012) were higher in the MSAs-negative group. Additionally, the percentage of CD4+TNFα+ (P=0.040), CD4+IFNγ+ (P=0.037), and CD4+IL-2+ (P=0.018) cells among total CD4+ T cells were higher in the MSA-negative DM patients compared with the MSAs-positive DM patients. Besides, MSAs-negative patients demonstrated a more favorable prognosis than MSAs-positive patients. Multivariable regression analysis identified advanced onset age, higher level of carcinoembryonic antigen (CEA), and RP-ILD as risk factors for mortality in DM patients. Conclusions Compared with MSAs-positive group, MSAs-negative DM patients suffered less from organ involvement compared with MSAs-positive group and tend to have better prognosis. Key Points MSAs-negative DM patients exhibited distinct characteristics in comparison with MSAs-positive DM patients: • The MSAs (−)/MAAs (+) DM patients demonstrated a higher prevalence of organizing pneumonia (OP) and usual interstitial pneumonia (UIP), and elevated eosinophil counts in bronchoalveolar lavage fluid. • CEA levels were lower in MSAs-negative patients compared with MSAs-positive patients. • Elevated counts of lymphocytes and CD16+CD56+ NK cells were identified in the MSAs-negative patients. Additionally, proportions of CD4+TNFα+, CD4+IFNγ+, and CD4+IL-2+ cells among total CD4+ T cells were higher in the MSAs-negative DM patients compared with DM MSAs-positive DM patients. • MSAs-negative DM patients had a more favorable prognosis than MSAs-positive DM patients. A multivariable regression analysis revealed the advanced onset age, high CEA levels, and RP-ILD were risk factors for mortality in DM patients.